Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance

Biomedical Chromatography

Volumn 18, Issue 6, 2004, Pages 400-402

  Stokvis, E ^a   Rosing, H ^a   Lopez Lazaro L ^b   Schellens, J H M ^a,c   Beijnen, J H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b PHARMAMAR S A   (Spain)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Human plasma; Kahalalide F; Multiple reaction monitoring LC MS MS; Solid phase extraction

Indexed keywords

PHASE SEPARATION; PLASMA (HUMAN);

A-STABLE; ANTICANCER DRUG; HUMAN PLASMAS; ISOTOPICALLY LABELLED INTERNAL STANDARDS; KAHALALIDE F; LC-MS-MS; MULTIPLE REACTION MONITORING; MULTIPLE REACTION MONITORING LC-MS/MS; PERFORMANCE; SOLID-PHASE EXTRACTION;

ASSAYS;

ANTINEOPLASTIC AGENT; KAHALALIDE F; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; ASSAY; CONTROLLED STUDY; DEVICE; DRUG STRUCTURE; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; STANDARD;

EID: 4344663297     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.392     Document Type: Article

References (4)

1. Johnstone RAW and Rose ME. Mass Spectrometry for Chemists and Biochemists, Chap. 7. Cambridge University Press: Cambridge, 1996.
2. Sancho JV, Pozo OJ, López FJ and Hernández F. Different quantitation approaches for xenobiotics in human urine samples by liquid chromatography/electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2002; 16: 639.
3. Stokvis E, Rosing H, López-Lázaro L, Rodriguez I, Jimeno J, Supko JG, Schellens JHM and Beijnen JH. Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. Journal of Mass Spectrometry 2002; 37: 992.
4. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation, 2001;www.fda.gov/cder/guidance/4252fnl.htm.